Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • 2024
  • Published:

Psychiatric disorders

An ancient psychedelic for traumatic brain injury

Nature Medicine volume 30, pages 342–343 (2024)Cite this article

Subjects

In military veterans with traumatic brain injury, treatment with ibogaine plus magnesium led to dramatic clinical improvements and a favorable safety profile; further studies with state-of-the art safety monitoring will be crucial to unlocking the potential benefits of this psychedelic compound.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Ibogaine plus magnesium treatment for traumatic brain injury.

References

  1. Suitt, T. H. High Suicide Rates Among United States Service Members and Veterans of the Post-9/11 Wars https://go.nature.com/3RQJ9Qm (Brown Univ., 2021).

  2. Siddiqi, S. H. et al. J. Neurotrauma 36, 1361–1374 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  3. Siddiqi, S. H. et al. Sci. Transl. Med. 15, eabn0441 (2023).

    Article  PubMed  Google Scholar 

  4. Mosca, A. et al. Curr. Neuropharmacol. 21, 2178–2194 (2023).

    Article  CAS  PubMed  Google Scholar 

  5. Cherian, K. et al. Nat. Med. https://doi.org/10.1038/s41591-023-02705-w (2024).

    Article  PubMed  Google Scholar 

  6. Canady, V. A. Ment. Health Wkly 33, 3–5 (2023).

    Google Scholar 

  7. Jones, B. D. M. et al. JAMA Netw. Open 4, e2125531–e2125531 (2021).

    Article  ADS  PubMed  PubMed Central  Google Scholar 

  8. Sonawalla, S. B. & Rosenbaum, J. F. Dialogues Clin. Neurosci. 4, 105–113 (2002).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Palm, S. T. et al. Preprint at bioRxiv https://doi.org/10.1101/2023.06.05.543261 (2023).

  10. Meisner, J. A., Wilcox, S. R. & Richards, J. B. Ther. Adv. Psychopharmacol. 6, 95–98 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. O’Brien, B., Wilkinson, S. T. & Mathew, S. J. Am. J. Psychiatry 179, 393–394 (2022).

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Disclaimers: The opinions and assertions expressed herein are those of the authors and do not necessarily reflect the official policy or position of the Uniformed Services University, the Department of Defense, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., or other government agency.

Author information

Authors and Affiliations

  1. Department of Neurology, Military Traumatic Brain Injury Initiative, Uniformed Services University of the Health Sciences, Bethesda, MD, USA

    David L. Brody

  2. Department of Psychiatry, Harvard Medical School, Brigham & Women’s Hospital (BWH), BWH Center for Brain/Mind Medicine, BWH Center for Brain Circuit Therapeutics, Boston, MA, USA

    Shan H. Siddiqi

Authors
  1. David L. Brody
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shan H. Siddiqi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David L. Brody.

Ethics declarations

Competing interests

D.L.B.: employee of the US Department of Defense. Research currently funded by Department of Defense. Holds equity in Inner Cosmos LLC. Receives royalties from sales of Concussion Care Manual (Oxford Univ. Press) and honoraria from Mary Ann Liebert, Inc., publisher of the Journal of Neurotrauma, for services as editor-in-chief. Performs consulting for Pfizer Inc., Intellectual Ventures, Signum Nutralogix, Kypha Inc., Sage Therapeutics, iPerian Inc., Navigant, Avid Radiopharmaceuticals (Eli Lilly & Co.), the St. Louis County Public Defender, the United States Attorney’s Office, the St. Louis County Medical Examiner, GLG and Stemedica. None of these entities were directly involved in the present work. S.H.S.: owner of intellectual property involving the use of brain connectivity to target transcranial magnetic stimulation, scientific consultant for Magnus Medical, performs investigator-initiated research funding from Neuronetics and Brainsway, receives speaking fees from Brainsway and Otsuka (for PsychU.org) and is a shareholder in Brainsway (publicly traded) and Magnus Medical (not publicly traded). None of these entities were directly involved in the present work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brody, D.L., Siddiqi, S.H. An ancient psychedelic for traumatic brain injury. Nat Med 30, 342–343 (2024). https://doi.org/10.1038/s41591-023-02759-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-023-02759-w

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing